News & Updates
Filter by Specialty:
Diabetics with severe insulin resistance exhibit poor physical fitness
Individuals with severe insulin-resistant diabetes (SIRD) appear to have the lowest physical fitness compared with other diabetes subgroups despite similar endothelial function across all cohorts, a study has shown. Moreover, those with severe autoimmune diabetes (SAID) have the lowest cardiovascular risk within the first year following diagnosis relative to other clusters.
Diabetics with severe insulin resistance exhibit poor physical fitness
01 Apr 2022
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
01 Apr 2022
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
01 Apr 2022
Exclusionary testing most efficient and cost-saving for NSCLC
Exclusionary testing, involving upfront testing for EGFR and ALK followed by next-generation sequencing (NGS) for other genomic alterations (GAs), is the most efficient and cost-saving molecular testing strategy for patients with metastatic non-small-cell lung cancer (NSCLC) in Hong Kong and perhaps East Asia, researchers from the Chinese University of Hong Kong (CUHK) have reported.
